Literature DB >> 16027732

Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation.

Akifumi Kanda1, Hidehiko Kawai, Shiho Suto, Shojiro Kitajima, Sunao Sato, Takashi Takata, Masaaki Tatsuka.   

Abstract

Aurora-B, previously known as AIM-1, is a conserved eukaryotic mitotic protein kinase. In mammals, this kinase plays an essential role in chromosomal segregation processes, including chromosome condensation, alignment, control of spindle checkpoints, chromosome segregation, and cytokinesis. Aurora-B is overexpressed in various cancer cells, suggesting that the kinase activity perturbs chromosomal segregation processes. Its forced overexpression induces chromosomal number instability and progressive tumorigenicity in rodent cells in vitro and in vivo. Nevertheless, based on focus formation in BALB/c 3T3 A31-1-1 cells, Aurora-B is not oncogenic. Here, we show that Aurora-B kinase activity augments Ras-mediated cell transformation. RNA interference with short hairpin RNA inhibits transformation by Ras and its upstream oncogene Src, but not by the downstream oncogene Raf. In addition, the inner centromere protein, which is a passenger protein associated with Aurora-B, has a similar ability to potentiate the activity of oncogenic Ras. These data indicate that elevated Aurora-B activity promotes transformation by oncogenic Ras by enhancing oncogenic signaling and by converting chromosome number-stable cells to aneuploid cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16027732     DOI: 10.1038/sj.onc.1208884

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

Review 1.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

Review 2.  Target validation and biomarker identification in oncology : the example of aurora kinases.

Authors:  Riccardo Colombo; Jürgen Moll
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

3.  Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.

Authors:  Danielle C Chinn; William S Holland; Philip C Mack
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-23       Impact factor: 4.553

4.  Aurora-B regulates RNA methyltransferase NSUN2.

Authors:  Shiho Sakita-Suto; Akifumi Kanda; Fumio Suzuki; Sunao Sato; Takashi Takata; Masaaki Tatsuka
Journal:  Mol Biol Cell       Date:  2007-01-10       Impact factor: 4.138

5.  Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.

Authors:  Lifang Xie; Michelle Kassner; Ruben M Munoz; Qiang Q Que; Jeff Kiefer; Yu Zhao; Spyro Mousses; Hongwei H Yin; Daniel D Von Hoff; Haiyong Han
Journal:  Biochem Pharmacol       Date:  2011-11-15       Impact factor: 5.858

6.  Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

Authors:  Bob Löwenberg; Petra Muus; Gert Ossenkoppele; Philippe Rousselot; Jean-Yves Cahn; Norbert Ifrah; Giovanni Martinelli; Sergio Amadori; Ellin Berman; Pieter Sonneveld; Mojca Jongen-Lavrencic; Sophie Rigaudeau; Paul Stockman; Alison Goudie; Stefan Faderl; Elias Jabbour; Hagop Kantarjian
Journal:  Blood       Date:  2011-10-05       Impact factor: 22.113

Review 7.  Aurora B kinase: a potential drug target for cancer therapy.

Authors:  Azaj Ahmed; Anas Shamsi; Taj Mohammad; Gulam Mustafa Hasan; Asimul Islam; Md Imtaiyaz Hassan
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-28       Impact factor: 4.553

8.  Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation.

Authors:  Anjali Mishra; Shujun Liu; Gregory H Sams; Douglas P Curphey; Ramasamy Santhanam; Laura J Rush; Deanna Schaefer; Lauren G Falkenberg; Laura Sullivan; Laura Jaroncyk; Xiaojuan Yang; Harold Fisk; Lai-Chu Wu; Christopher Hickey; Jason C Chandler; Yue-Zhong Wu; Nyla A Heerema; Kenneth K Chan; Danilo Perrotti; Jianying Zhang; Pierluigi Porcu; Frederick K Racke; Ramiro Garzon; Robert J Lee; Guido Marcucci; Michael A Caligiuri
Journal:  Cancer Cell       Date:  2012-11-13       Impact factor: 31.743

9.  Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Giovanni Martinelli; Elias J Jabbour; Alfonso Quintás-Cardama; Kiyoshi Ando; Jacques-Olivier Bay; Andrew Wei; Stefanie Gröpper; Cristina Papayannidis; Kate Owen; Laura Pike; Nicola Schmitt; Paul K Stockman; Aristoteles Giagounidis
Journal:  Cancer       Date:  2013-04-19       Impact factor: 6.860

10.  The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma.

Authors:  Lkhagva-Ochir Tovuu; Tohru Utsunomiya; Satoru Imura; Yuji Morine; Tetsuya Ikemoto; Yusuke Arakawa; Hiroki Mori; Jun Hanaoka; Mami Kanamoto; Koji Sugimoto; Yu Saito; Shinichiro Yamada; Michihito Asanoma; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2013-07-27       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.